Related Experiment Video
Updated: Jun 1, 2026

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease
Published on: October 4, 2021
Neuroleptic malignant syndrome associated with bromocriptine withdrawal in Parkinson's disease--a case report
Yung-Fu Wu1, Yuk-Shing Kan, Chen-Hong Yang
1Department of Psychiatry, Armed Forces Beitou Hospital, Taipei 112, Taiwan.
Abstract:
A 74-year-old man had 15-year history of Parkinson's disease and received bromocriptine monotherapy for 3 years. We present the first case report of neuroleptic malignant syndrome associated with the withdrawal of bromocriptine. The symptoms were alleviated by adequate replenishment of intravenous fluid, temperature reduction and replacement of bromocriptine. Clinicians need to be aware of this potential complication and that a thorough history of current medications is crucial to its identification.
Related Concept Videos
Parkinson's Disease: Overview
Parkinson's Disease: Treatment
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson Disease l: Introduction
Alterations in Muscle Tone lll
Parkinson Disease ll: Pathophysiology
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists
Phenothiazines, such as prochlorperazine...
